SCHEMBL16636964

SCHEMBL16636964

CCCCCCCC/C=C\CCCCCCCC(=O)OCC1COC(C)(C)O1

nearest known ligand 0.87

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11086686 1.00 LPAR1 (0.56) LPAR1
SCHEMBL24625000 0.97 LPAR1 (0.53) LPAR1
SCHEMBL5936343 0.93 LPAR1 (0.51) LPAR1
SCHEMBL8277024 0.93 LPAR1 (0.51) LPAR1
SCHEMBL31520002 0.93 LPAR1 (0.51) LPAR1
SCHEMBL6805094 0.93 LPAR1 (0.51) LPAR1
SCHEMBL9905957 0.91 LPAR1 (0.47) LPAR1
SCHEMBL10597149 0.90 ALDH1A1 (0.56)
SCHEMBL9905966 0.90 ALDH1A1 (0.56)
SCHEMBL16140067 0.90 ALDH1A1 (0.56)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3065732-A1 COMPOUNDS, COMPOSITIONS AND USES THEREOF FOR THE PREVENTION AND/OR TREATMENT OF DYSLIPIDEMIA Centre National de la Recherche Scientifique (CNRS) (FR) 2016-09-14 EP claimed
WO-2015052237-A1 COMPOUNDS, COMPOSITIONS AND USES THEREOF FOR THE PREVENTION AND/OR TREATMENT OF DYSLIPIDEMIA CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2015-04-16 WO claimed
CN-105744934-B Composition for preventing or treating the compound of dyslipidemia and comprising this kind of compound 法国国家科学研究中心 2019-08-20 CN disclosed
US-10231985-B2 Compounds and compositions comprising such compounds for the prevention or treatment of dyslipidaemias CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2019-03-19 US disclosed
US-10231985-B2 Compounds and compositions comprising such compounds for the prevention or treatment of dyslipidaemias CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2019-03-19 US disclosed
US-9821000-B2 Compounds, compositions and corresponding uses for preventing and/or treating of dyslipidemia CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2017-11-21 US disclosed
US-9821000-B2 Compounds, compositions and corresponding uses for preventing and/or treating of dyslipidemia CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2017-11-21 US disclosed
US-20160287542-A1 COMPOUNDS, COMPOSITIONS AND CORRESPONDING USES FOR PREVENTING AND/OR TREATING OF DYSLIPIDEMIA UNIVERSITE DE POITIERS (FR) 2016-10-06 US disclosed
US-20160287542-A1 COMPOUNDS, COMPOSITIONS AND CORRESPONDING USES FOR PREVENTING AND/OR TREATING OF DYSLIPIDEMIA UNIVERSITE DE POITIERS (FR) 2016-10-06 US disclosed
EP-3065732-A1 COMPOUNDS, COMPOSITIONS AND USES THEREOF FOR THE PREVENTION AND/OR TREATMENT OF DYSLIPIDEMIA Centre National de la Recherche Scientifique (CNRS) (FR) 2016-09-14 EP disclosed
EP-3065733-A1 COMPOUNDS AND COMPOSITIONS COMPRISING SUCH COMPOUNDS FOR THE PREVENTION OR TREATMENT OF DYSLIPIDAEMIAS Centre National De La Recherche Scientifique (FR) 2016-09-14 EP disclosed
US-20160256429-A1 COMPOUNDS AND COMPOSITIONS COMPRISING SUCH COMPOUNDS FOR THE PREVENTION OR TREATMENT OF DYSLIPIDAEMIAS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2016-09-08 US disclosed
US-20160256429-A1 COMPOUNDS AND COMPOSITIONS COMPRISING SUCH COMPOUNDS FOR THE PREVENTION OR TREATMENT OF DYSLIPIDAEMIAS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2016-09-08 US disclosed
US-20150321992-A1 TRIACYLGLYCEROL OLIGOMERS TRENT UNIVERSITY (CA) 2015-11-12 US disclosed
WO-2015052237-A1 COMPOUNDS, COMPOSITIONS AND USES THEREOF FOR THE PREVENTION AND/OR TREATMENT OF DYSLIPIDEMIA CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2015-04-16 WO disclosed
WO-2015052433-A1 COMPOUNDS AND COMPOSITIONS COMPRISING SUCH COMPOUNDS FOR THE PREVENTION OR TREATMENT OF DYSLIPIDAEMIAS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160287542-A1 COMPOUNDS, COMPOSITIONS AND CORRESPONDING USES FOR PREVENTING AND/OR TREATING OF DYSLIPIDEMIA LIPC, CPT1A, LIPA LPAR1 103/4885
US-20160256429-A1 COMPOUNDS AND COMPOSITIONS COMPRISING SUCH COMPOUNDS FOR THE PREVENTION OR TREATMENT OF DYSLIPIDAEMIAS LIPC, FABP4, PNLIP LPAR1 224/4885
US-20150321992-A1 TRIACYLGLYCEROL OLIGOMERS SQLE, DGAT2, PNLIP LPAR1 198/4885
US-10231985-B2 Compounds and compositions comprising such compounds for the prevention or treatment of dyslipidaemias LIPC, FABP4, PNLIP LPAR1 224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.